[Asia Economy Reporter Ji Yeon-jin] Inbiogen soared to the daily price limit on the 6th following the news of a successful development of a preventive substance against COVID-19 variants by an investment company.
Inbiogen recorded 4,425 won, up 29.96% from the previous day, within just 20 minutes after the market opened on the Korea Exchange.
Earlier, the Vascular Research Division of the Institute for Basic Science stated, "If nasal ciliated cells continue to be damaged, the virus can rapidly spread to other organs such as the lungs, so a vaccine that sprays medication into the nose to form mucosal immunity could become a new strategy for COVID-19 prevention and treatment."
Haim Bio, the largest shareholder of Inbiogen, is reported to have started producing a COVID-19 preventive spray product.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
